EC
BMRN icon

Eleva Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eleva Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.7M Buy
31,339
+7,920
+34% +$453K 0.45% 10
2025
Q2 		$1.29M Buy
+23,419
New +$1.38M 0.28% 18

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Eleva Capital's BMRN Position: Q3 2025 in Review

Eleva Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 34% in Q3 2025, buying an estimated $453K and bringing the position to 31,339 shares worth $1.7M. The position accounts for 0.45% of the portfolio, ranked #10.

Eleva Capital first reported a position in BMRN in Q2 2025 and has held it in 2 quarters since. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Eleva Capital held 31,339 shares of BioMarin Pharmaceuticals worth $1.7M as of Q3 2025.
  • Eleva Capital bought 7,920 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $453K.
  • BioMarin Pharmaceuticals made up 0.45% of Eleva Capital's portfolio in Q3 2025, its #10 holding.
  • Eleva Capital first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Eleva Capital's 13F filing for Q3 2025, filed 10 Nov 2025.